Abstract:

The study examined all the area councils within Federal Capital Territory Abuja, during the Covid 19 pandemic in order to critically appraise the extent of safety of orthodox vaccines and local herbal remedies. A total of 933 volunteers were involved. The adverse reactions post herbal and orthodox vaccinations were compared in order to ascertain which of the two regimes best suited the volunteers. Two sample sizes were estimated. One was based on the expected frequency of at least one local side effect between 48.9 and 85.8%. The second was based on the expected frequency of at least one systemic side effect between 52.6 and 70.5%. T-test calculated was far higher than the values tabulated at 99% confidence limits when the two independent population means of both volunteers that were administered with orthodox vaccine and those who received the local Joseleen lipids mixtures (JOHVIR) were compared. In other words, t-cal. 34.6> t –tab. 3.17 at P <0.01, Case fertility rates for the post orthodox vaccine administration was 14% in all the area councils unisex and across all age groups while no fatality cases were recorded post herbal lipids mixture administration to volunteers. This study provides novel evidence that there was high significant difference (P<0.01) in serious adverse reactions post orthodox vaccine administration and far milder and lesser adverse reactions post Local Joseleen Herbal Lipids mixture (Johvir) across all the ages tested.

References:

[1] Deng, S. Q. and Peng, H. J., (2020), Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. J Clin Med. 9(2):575. doi: 10.3390/jcm9020575. PMID: 32093211; PMCID: PMC7074453.

[2] Tiwari, R., Sircar, S., Bhat, S., Malik, Y.S., Singh, K.P., Chaicumpa, W., Bonilla-Aldana, D.K. and Rodriguez-Morales, A. J., (2020), Coronavirus disease 2019-Covid-19. Clin. Microbiol. Rev. 33, e00028-20.

[3] Liu, L., Lei, X., Xiao, X., Yang, J., Li, J., Ji, M., Du, W., Tan, H., Zhu, J., Li, B. and Jin, Z, (2020) Epidemiological and Clinical Characteristics of Patients with Coronavirus Disease-2019 in Shiyan City, China. Front. Cell. Infect. Microbiol. 10:284. doi: 10.3389/fcimb.2020.00284.

[4] Akihisa, T.N., Kojima, N., Katoh, Y., Ichimura, H., Suzuki, M., Fukatsu, S. and Maranz, E.T., (2010), Triterpene alcohol and fatty acid composition of shea nuts from seven African countries. J. Oleo Sci 59 (7) pp. 351-360, doi:10.5650/jos.59.351.

[5] Baden, L. R., El Sahly, H. M. and Essink, B., (2020), COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384(5):403-416. doi:10.1056/NEJMoa2035389.

[6] Mehrbod, P., Abdalla, M. A., Njoya, E. M., Ahmed, A. S., Fotouhi, F. and Farahmand, B., (2018), South African medicinal plant extracts active against influenza A virus. BMC Complement. Altern. Med. 18 (1), 1–10. 10.1186/s12906-018-2184-y.

[7] Hensel, A., Bauer, R., Heinrich, M., Spiegler, V., Kayser, O. and Hempel, G., (2020), Challenges at the time of Covid-19: opportunities and innovations in Antivirals from nature. Planta Med. 86 (10), 659. 10.1055/a-1177- 4396.

[8] Fortner A, Schumacher D. First Covid-19 Vaccines Receiving the US FDA and EMA Emergency Use Authorization. Discoveries (Craiova). 2021 Mar 5;9(1): e122. doi: 10.15190/d.2021.1. PMID: 33969180; PMCID: PMC8101362.

[9] Gee, J., Marquez, P. and Su, J., (2021), First month of Covid-19 vaccine safety monitoring—United States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep 70(8):283-288. doi: 10.15585/mmwr.mm7008e3.

[10] Voysey, M., and Clemens, S. A. C., (2021), Oxford Covid Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet.397 (10269):99-111. doi:10.1016/S0140-6736(20)32661.

[11] Menni, C., Klaser, K., May, A. and Spector, T. D., (2021), Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the Covid Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis.21(7):939-949. doi: 10.1016/S1473-3099(21)00224-3 PMID: 33930320; PMCID: PMC8078878.

[12] Ajobiewe, J.O., Ajobiewe, H.F., Ogundeji, A.A., Umeji, L.C., Umeji, C., and Ajobiewe, D.C., (2020), Medical Potential of a Locally Sourced Lipids Mixture on Confirmed Corona Virus Infected Patients and Those At Risk of Infection, Attending National Hospital Abuja, Nigeria. -An Evidence Based Approach. Scholars Journal of Medical Case Reports. 8. 846-853. 10.36347/sjmcr. 2020.v08i09.011.

[13] Fortner, A., Schumacher, D., (2021), First Covid-19 Vaccines Receiving the US FDA and EMA Emergency Use Authorization. Discoveries (Craiova);9(1): e122. doi: 10.15190/d.2021.1. PMID: 33969180; PMCID: PMC8101362.

[14] Ojo, O. and Ndinteh, T., (2021), Traditional uses, phytochemistry, pharmacology and other potential applications of Vitellaria paradoxa (Sapotaceae): https://doi.org/10.1016/j.arabjc.2021.103213.

[15] Olusesan, O., Micheal, H. K., and Kengne, M. C., (2021), Traditional uses, phytochemistry, pharmacology and other potential applications of Vitelleria paradoxa Gaertin. (Sapotacaea): Arabian Journal of Chemistry, Vol 14, Issue 7, 2021, 103213, ISSN 1878 – 5352, https://doi. org/10.1016/j.Arabic. 2021. 103213. https://www.Sciencedirect.com/science/article/pii/S1878535221002288.

[16] World Health Organization (2021): Coronavirus Disease vaccine: is there a vaccine for Covid-19 FAQ [Online]. Available from: https://www.who.int/news-room/q-a-detail/coronavirus-disease-(Covid-19)-vaccines).

[17] Soyemi, K. V., Olagoke, E., Olomofe, C., (2021), Covid-19 Vaccine: Newspaper Coverage of the side effects of the vaccine in Nigeria medRxiv10.02.21264454; doi: https://doi.org/10.1101/2021.10.02.21264454.

[18] National Primary Healthcare Development Agency (2021) [Online]. Available from: https://www.facebook.com/NPHCDA/posts/4463147467043205.

[19] Attah, A. F., Fagbemi, A. A., Olubiyi, O., Dada-Adegbola, H., Oluwadotun, A., Elujoba, A., Babalola, C. P., (2021), Therapeutic Potentials of Antiviral Plants Used in Traditional African Medicine with Covid-19 in Focus: A Nigerian Perspective. Front Pharmacol. 26; 12:596855. doi: 10.3389/fphar.2021.596855. Erratum in: Front Pharmacol; 12:721060. PMID: 33981214; PMCID: PMC8108136.

[20] Ioannidis, J.P.A., Axfors, C., and Contopoulos-Ioannidis, D.G., (2020), Population-level Covid-19 mortality risk for non-elderly individuals overall and for non-elderly without underlying diseases in pandemic epicenters. Environ.Res188:109890. doi: 101016/j.envres.2020.109890.